Regeneron Pharmaceuticals

Amgen's Phase III VESALIUS-CV trial met both primary endpoints, demonstrating that Repatha significantly reduces major adverse cardiovascular events in high-risk patients without prior heart attack or stroke.

Regeneron's Phase 3 OPTIMA trial of garetosmab met its primary endpoint, demonstrating a 90% or greater reduction in new heterotopic ossification lesions in adults with fibrodysplasia ossificans progressiva at 56 weeks.

Ollin Biosciences launched with $100 million in Series A funding led by ARCH Venture Partners, Mubadala Capital, and Monograph Capital to develop next-generation ophthalmology treatments.

Dualitas Therapeutics launched from stealth with $65 million Series A funding co-led by Versant Ventures and Qiming Venture Partners USA, with participation from Eli Lilly and Company and other strategic investors.

The Federal Court of Australia denied Regeneron and Bayer's preliminary injunction application against Sandoz's aflibercept biosimilars, allowing the launch of Afqlir and Enzeevu to proceed as planned.

Regeneron's Phase 3 EMPOWER-Lung 3 trial shows Libtayo plus chemotherapy achieved a 19.4% five-year survival rate compared to 8.8% with chemotherapy alone in advanced non-small cell lung cancer patients.

Sandoz reached a patent settlement agreement with Regeneron resolving all litigation related to its FDA-approved aflibercept biosimilar Enzeevu, clearing the path for US market entry by the fourth quarter of 2026.

Regeneron's investigational allergen-blocking antibodies achieved significant symptom reduction in Phase 3 trials, with cat allergy treatments reducing ocular itch by 52% and birch allergy treatments reducing itch by 51% compared to placebo.

Sanofi's experimental atopic dermatitis drug amlitelimab met all primary endpoints in Phase III trials but showed weaker efficacy compared to the company's blockbuster drug Dupixent.

Merck KGaA has appointed David Weinreich as Global Head of R&D and Chief Medical Officer for its Healthcare business sector, bringing over 20 years of experience and leadership in developing 15 approved drugs worldwide.